14/06/2023 • DIVANI CARAVEL HOTEL | ΜΑΚΕDΟΝΙΑ HALL
HTA: Setting goals for an innovative future
The right drug to the right patient, at the right time, at the right price.
With the participation of 30 distinguished Greek and foreign speakers and more than 250 participants, including health professionals, researchers, academics, policy makers, industry representatives and patients, the largest annual conference on the Evaluation of Health Technologies (HTA) in Greece, organized by Health Daily and BOUSSIAS EVENTS, was concluded successfully. The 8th HTA conference, under the specific title: Setting goals for an innovative future, took place on June 14, 2023 in Athens at the DIVANI CARAVEL Ηotel.
The main theme of the 2023 HTA conference was the new role that HTA and Negotiations are called upon to take on, in the context of new EU Regulation on Health Technology Assessment which will allow vital and innovative health technologies – such as innovative medicines, certain medical devices, medical equipment and prevention and treatment methods – to be more widely available.
Significant interventions were made by both institutions and industry and offered an opportunity to discuss in depth the strategies, procedures, skills and capabilities needed to address challenges and overcome potential barriers to access many new and innovative therapies. After 5 years of operation of the HTA Committee and the Medicines’ Price Negotiation Committee, it was the right time to take a look back and reference to their difficulties, challenges and achievements as well as to assess the impact of these reforms on Greece’s pharmaceutical policy, setting goals towards an innovative future.
The conference was held under the auspices of the Panhellenic Pharmaceutical Industry Union (PEF), the Hellenic Market Access Union (ELEMA), the Hellenic Association of Pharmaceutical Companies (SFEE) and the PhRMA Innovation Forum (PIF).
The main theme of the 2023 HTA conference is the new role that HTA and Negotiations are called upon to take on, in the context of new EU Regulation on Health Technology Assessment which will allow vital and innovative health technologies – such as innovative medicines, certain medical devices, medical equipment and prevention and treatment methods – to be more widely available. To this end, we have to work together to set goals for an innovative future.
For the health technology assessment (HTA) community to transition and for individual HTA bodies to find their place in a more proactive, global ecosystem that considers whole system value, key questions must be urgently addressed with stakeholders across the lifecycle.
In addition, the role of HTA and Negotiations Committee in health policy as primarily a tool for setting priorities, allocating resources, budgeting, and re-evaluating/ re-negotiating, in an ever-changing environment, with digital technologies and big data promising access to data that will lead to greater transparency and better-informed decisions.
The conference will offer an opportunity to discuss in depth the strategies, procedures, skills and capabilities needed to address challenges and overcome potential barriers to access to many new and innovative therapies.
Last but not least, after 5 years of operation of the HTA Committee and the Medicines’ Price Negotiation Committee, it is the right time to take a look back and reference to their difficulties, challenges and achievements as well as to assess the impact of these reforms on Greece’s pharmaceutical policy.
Speakers
Key Sessions will focus on:
- The new role of HTA and Negotiations in the context of the new EU Regulation on HTA
- Building Capacities for HTA: Challenges and Opportunities for strenghtening the HTA Institution, Process, and Methods
- Towards more Effective use of Innovative Models to Facilitate the Negotiation Outcome and ensure Affordability and Accessibility of Medicines
- Improving Access for Digital Platforms and Medical Devices
- The Regulation on Health Technology Assessment, a key deliverable of the European Pharmaceutical Strategy
- The EU HTA Implications for Companies – What to Prepare for 2025
- EU HTA: will it facilitate or hinder patient access to new medicines?
- The Convergence of HTA and Regulation: A New HTA Reality and Collaboration with Regulatory Agencies
- HTA trends in EU countries
- HTA committee performance in Greece and future strategy
- Exploring the Assessment Criteria in HTA and their relative weight
- Optimization of HTA Processes in Greece
- What is driving HTA decision-making? Evidence from cancer medicines reimbursement decision in other European countries
- Addressing current and future HTA challenges for improving patients’ access
- Principles and Challenges of HTA for biomarker tests and personalized medicine technologies
- Medicines Negotiation Committee performance in Greece and future strategy
- Financial negotiations: Are discounts a threat to the quality of care?
- How GR is going to fund Innovation and Advanced Therapeutic Medicinal Products (ATMPs)
- Implementation of Managed Entry Agreements: practical experience and local challenges
- Implementing Risk-sharing Agreements for innovative Medicines
- Medicines negotiation committee as a tool for optimizing pharmaceutical expenditure (i.e disinvestments, reassessments etc)
- Greek Experience Assessing Innovative Medical Devices and Future Strategy
- The new DRG Framework
- Enhancing access of innovative medical technologies in GR
- Challenges resulting from the experience of HTA for Medical Devices
Who should Attend?
- Healthcare Stakeholders
- Government representatives
- Pharmaceutical industry executives (Market Access, Government Affairs, Health Economics) Public & Private Health services providers
- Health economists
- Academics
- Physicians
- Patient advocates & patient group representatives
Testimonials
Grand Sponsor
GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
We deliver more than 50 innovative medicines for diseases such as diseases of the respiratory system (chronic obstructive pulmonary disease and asthma), HIV/AIDS, rare diseases and oncology. In parallel, as a leader in vaccine development, we provide vaccines for the prevention of the total diseases which are described in the National Vaccination Programme for children and adolescents.
Our values and expectations are at the core of our activities, enabling us to deliver our ambition and purpose to unite science, technology and talent to get ahead of disease together.
Sponsors
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Health Through Evidence (HTE) is a leading provider of health economics and market access services for the pharmaceutical, biotech, and medical device industry. We provide evidence-based solutions to generate a greater understanding of the clinical and economic value of your products for payers, regulators, patients, and prescribers. Our expertise spans health economics, health technology assessments, market access strategy, real world evidence generation, data analytics, systematic literature reviews, medical writing, stakeholder engagement and value communication.
Learn more at: hte.gr and follow us on LinkedIn Health Through Evidence
Inspired by the synthesis of key-words Health, IT and Think, HealThink was founded to provide high class market access, health technology assessment (HTA) and R&D services in health sector. Based on a long experience on Medical/Scientific Coordination of HTA, digital health and RWD projects, a multidisciplinary team of professionals with diverse scientific background has been created, able to respond to highly demanding projects. HealThink’s expertise in HTA for pharmaceutical products, medical devices and digital health, but also in outcomes research and data analytics has led to long-term and extensive collaboration with pharma/medical devices industry, scientific associations and academic/research organisations, both locally and internationally. Website: www.healthink.info
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Solutions are powered by the IQVIA CORE™, which combines big data, advanced technology, analytics and extensive industry knowledge. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 70,000 employees worldwide. Learn more at iqvia.com.
Supporters
Under the Auspices
Media Partner
Media Sponsors
Audiovisual Sponsor
CONEQ provides technical equipment and services to any kind of event. With our Simultaneous Interpretation Systems, Conference Systems, AudioVisual Equipment we support events and provide the best service to our customers. Our professionalism, our high quality of service and state of the art equipment offered to over 600 large and of great significance conferences during the last 5 years have certainly contributed to our constant uptrend. Call us at (+30) 211 2163453. or email us at [email protected]
Organized by
Contact us
Valya Kyritsi, T: +30 210 6617 777 (ext. 227), E: [email protected]